SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 03 2022
Historique:
received: 30 07 2021
revised: 12 01 2022
accepted: 13 01 2022
pubmed: 6 2 2022
medline: 22 3 2022
entrez: 5 2 2022
Statut: ppublish

Résumé

Zika virus (ZIKV) is a member of the Flaviviridae family that can cause neurological disorders and congenital malformations. The NS2B-NS3 viral serine protease is an attractive target for the development of new antiviral agents against ZIKV. We report here a SAR study on a series of substrate-like linear tripeptides that inhibit in a non-covalent manner the NS2B-NS3 protease. Optimization of the residues at positions P1, P2, P3 and of the N-terminal and C-terminal portions of the tripeptide allowed the identification of inhibitors with sub-micromolar potency with phenylglycine as arginine-mimicking group and benzylamide as C-terminal fragment. Further SAR exploration and application of these structural changes to a series of peptides having a 4-substituted phenylglycine residue at the P1 position led to potent compounds showing double digit nanomolar inhibition of the Zika protease (IC

Identifiants

pubmed: 35123179
pii: S0968-0896(22)00023-2
doi: 10.1016/j.bmc.2022.116631
pii:
doi:

Substances chimiques

Antiviral Agents 0
NS2B protein, flavivirus 0
NS3 protein, flavivirus 0
Peptides 0
Protease Inhibitors 0
Viral Nonstructural Proteins 0
Serine Endopeptidases EC 3.4.21.-
RNA Helicases EC 3.6.4.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

116631

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Stefania Colarusso (S)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy. Electronic address: s.colarusso@irbm.com.

Federica Ferrigno (F)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Simona Ponzi (S)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Francesca Pavone (F)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Immacolata Conte (I)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Luigi Abate (L)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Elisa Beghetto (E)

Department of Discovery Biology, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Antonino Missineo (A)

Department of Discovery Biology, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Jerome Amaudrut (J)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Alberto Bresciani (A)

Department of Translational Biology, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Giacomo Paonessa (G)

Department of Discovery Biology, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Licia Tomei (L)

Department of Discovery Biology, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Christian Montalbetti (C)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Elisabetta Bianchi (E)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Carlo Toniatti (C)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Jesus M Ontoria (JM)

Department of Drug Discovery, IRBM S.p.A, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy. Electronic address: j.ontoria@irbm.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH